Impact of baseline glucocorticoids (GCs) on cardiotoxic events and myocardial damage related to immune checkpoint inhibitors: a retrospective clinical research
GCs ≥ 20 mg during the first ICIs treatment cycle is significantly associated with the reduced risks of both ICIs-associated CEs and MD.
Authors
- Yawen Chen (ORCID: https://orcid.org/0000-0001-7006-2459)
- Haixia Zhang (ORCID: https://orcid.org/0000-0001-8196-2479)
- Yanli Qiao
- Qiaoling Zhu (ORCID: https://orcid.org/0000-0002-0923-5629)
- Xin Lv (ORCID: https://orcid.org/0000-0003-3889-9085)
- Qiaoyun Wang (ORCID: https://orcid.org/0000-0003-4801-8085)
Institutions
- Macau University of Science and Technology (MO)
- China Pharmaceutical University (CN)
- Xuzhou Medical College (CN)
- Nanjing Drum Tower Hospital (CN)
- Nanjing Medical University (CN)
- Nanjing University (CN)
Publication Details
- Journal
- Expert Opinion on Drug Safety
- Published
- 2025-02-15
- DOI
- https://doi.org/10.1080/14740338.2025.2467814
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05
Funders
- National Natural Science Foundation of China